Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35524952.
- Also identified by DOI 10.1093/infdis/jiac192 and PMC identifier 9129162.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Health jurisdictions have seen a near-disappearance of respiratory syncytial virus (RSV) during the first year of the coronavirus disease 2019 (COVID-19) pandemic. Over this corresponding period, we report a reduction in RSV antibody levels and live virus neutralization in sera from women of childbearing age and infants between May to June 2020 and February to June 2021, in British Columbia (BC), Canada. This supports that antibody immunity against RSV is relatively short-lived and that maintaining optimal antibody levels in infants requires repeated maternal viral exposure. Waning immunity may explain the interseasonal resurgence of RSV cases observed in BC and other countries.
Medical subject headings
- Respiratory Syncytial Virus Infections
- COVID-19
- Respiratory Syncytial Virus, Human
- Respiratory Syncytial Virus Vaccines